Improving Strategies for Cancer Reduction through Early-detection and ENgagement (I-SCREEN) - Leveraging decades of NCI investments in clinical trials, data infrastructure, and cancer screening research, the I-SCREEN (Improving Strategies for Cancer Reduction through Early-detection and ENgagement) ACCESS Hub is well-positioned to efficiently and effectively address pressing issues around the emergence of new technologies for cancer screening. In collaboration with other ACCESS Hubs, we will evaluate the benefits and harms of new cancer screening technologies and their impacts on a representative sample of the United States (US) population. We will build on the University of Colorado Cancer Center’s (UCCC) successful administration of large cancer screening trials, including the Prostate, Lung, Ovarian, & Colorectal (PLCO) Cancer Screening Trial and the National Lung Screening Trial (NLST), along with their well-established Colorado Cancer Screening Program (CCSP), a statewide cancer screening network reaching the catchment area of the center. UCCC’s network of rural health centers will be complemented by Kaiser Permanente Colorado’s (KPCO) inclusive population from Colorado’s Front Range and extend existing collaborations between UCCC and KPCO in the NCI-funded Colorado Implementation Science Center for Cancer Control (COISC3). We will also build on the synergy between KPCO and Kaiser Permanente Hawaii (KPHI) as the only two sites in NCI’s Population-based Research to Optimize the Screen Process (PROSPR) Consortium that are also part of the Connect NCI Cohort Initiative and the Kaiser Permanente (KP) Research Bank (KP’s national biobank), both recruiting healthy patients and collecting blood biospecimens. The I-SCREEN Consortium consists of an NCI-designated Cancer Center, two integrated care delivery systems, one rural/suburban health system accepting >25 types of insurance, and one rural critical access hospital system. Our long-term goal is to reduce cancer-related mortality by rapidly investigating emerging, novel screening technologies in a population that is representative of the US population to ensure that efficacious new technologies have a broad reach. To accomplish this goal, we will: 1) collaborate with NCI, the CSRN Centers and ACCESS Hubs to build an ecosystem to evaluate new cancer screening technologies and strategies in multiple clinical settings; 2) Develop and execute the Vanguard feasibility study to inform the design of trials to evaluate new technologies for cancer screening of populations that are representative of the US population; and, 3) increase the impact of CSRN by collaborating with NCI to build a robust data/biospecimen repository available to CSRN investigators and external investigators for research to improve cancer screening and early detection and establish the provisioning of publicly available CSRN datasets. Through centralized Administrative, Recruitment and Biospecimens, Engagement, and Data Cores, we will ensure ACCESS Hub collaboration, communication, and progress towards CSRN deliverables. I-SCREEN will be a model for high-impact, translational research to test emerging cancer screening technologies to reduce cancer mortality in the US.
